Wealthquest Corp Buys Shares of 2,077 Repligen Corporation (NASDAQ:RGEN)

Wealthquest Corp bought a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,077 shares of the biotechnology company's stock, valued at approximately $264,000.

Several other institutional investors also recently bought and sold shares of the company. Oppenheimer & Co. Inc. purchased a new position in shares of Repligen in the fourth quarter worth $216,000. LPL Financial LLC increased its holdings in Repligen by 47.6% in the fourth quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock valued at $4,873,000 after buying an additional 10,395 shares in the last quarter. Signaturefd LLC increased its holdings in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares in the last quarter. US Bancorp DE increased its holdings in Repligen by 1.9% in the fourth quarter. US Bancorp DE now owns 10,222 shares of the biotechnology company's stock valued at $1,471,000 after buying an additional 190 shares in the last quarter. Finally, Zions Bancorporation N.A. increased its stake in shares of Repligen by 48.9% during the fourth quarter. Zions Bancorporation N.A. now owns 14,079 shares of the biotechnology company's stock worth $2,027,000 after purchasing an additional 4,626 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RGEN. Evercore ISI began coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Royal Bank Of Canada lowered their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a report on Tuesday, April 29th. Finally, Wall Street Zen upgraded Repligen from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $172.83.

Repligen Price Performance

Shares of Repligen stock traded down $0.65 on Friday, hitting $123.56. 851,478 shares of the company were exchanged, compared to its average volume of 730,842. The stock has a market capitalization of $6.94 billion, a price-to-earnings ratio of -274.58, a price-to-earnings-growth ratio of 3.56 and a beta of 1.10. The company has a 50-day moving average price of $128.10 and a 200 day moving average price of $141.03. Repligen Corporation has a 1-year low of $102.97 and a 1-year high of $182.52. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.